

1st LINE Therapeutic

Unresectable

UCI 01-61

A Humanitarian device exemption use protocol of TheraSphere for treatment of Unresectable Hepatocellular Carcinoma (Abi-Jaoudeh)

UCI 15-80

Phase III Comparing Pexa-Vec Followed by Sorafenib vs. Sorafenib Pts w/ HCC w/o Prior Systemic Therapy (Abi-Jaoudeh)

UCI 15-81

Phase 1 Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Hepatocellular Carcinoma (Abi-Jaoudeh)

UCI 16-40

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects with Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma (Imagawa)

LIVER CANCER

ECOG EAY131 (MATCH)

Molecular Analysis for Therapy Choice (Bota)

SWOG S1609

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)

Correlative

UCI 03-03 Immunologic Factors Affecting Outcomes in Patients with Liver Cancer (Imagawa)

UCI 16-29** Dynamic Contrast Enhanced Magnetic Resonance Imaging as a Biomarker to Predict Response to Liver Tumor Embolization (Lam)

2nd LINE Therapeutic

Unresectable or Metastatic

UCI 16-81

Comparing trans-arterial chemoembolization outcome using cone beam CT vs. conventional fluoroscopy (Abi-Jaoudeh)

UCI 16-94

Phase IIA Single Arm Study of Treatment of Patients with Advanced Liver Cancer with a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti-PD1 monoclonal antibody (Abi-Jaoudeh)

UCI 17-107

A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination with Bevacizumab Compared with Sorafenib in Patients with Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (Dayyani)